Childhood leukaemia: Towards improved tailored therapy

The Lancet Oncology

Volumn 11, Issue 5, 2010, Pages 403-404

  Pieters, Rob ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CLOFARABINE; DASATINIB; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; NILOTINIB; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHILDHOOD LEUKEMIA; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 21; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DIPLOIDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FOLLOW UP; GENE AMPLIFICATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; CHILD; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NOTE;

CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77952309576     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70101-7     Document Type: Note

References (10)

1. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010, published online Apr 20. 10.1016/S1470-2045(10)70066-8.
2. Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005, 105:4223-4225.
3. Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995, 85:751-756.
4. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998-1006.
5. Schultz KR, Bowman WP, Aledo A, et al. Improved early event free survival with imatinib in Philadelphia chromosome positive acute lymphoblastic leukaemia: a Childrens Oncology Group study. J Clin Oncol 2009, 27:5121-5123.
6. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002, 359:1909-1915.
7. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370:240-250.
8. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol 2009, 145:376-388. Childhood Acute Lymphoblastic Leukaemia Collaborative Group.
9. den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10:125-134.
10. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia. New Engl J Med 2009, 360:470-480.